To assessthe potential rolesofprotein Z(PZ) andprotein Z-dependentp roteasei nhibitor (ZPI) in venous thrombosis,t heir plasma levels were measured in 426 individuals with venous thrombosis and 471 control individualsp articipatingi nt he Leiden Thrombophilia Study. Arelationship between the levelof Keywords Coagulation inhibitors, clinical /epidemiologicalstudies, thrombophilia PZ or ZPI andvenous thrombosis wasnot detectedinthe overall case-controls tudy.PZa nd ZPI circulate as ac omplex and theirplasma levels areinterdependent. Both PZ and ZPIare increasedwith oral contraceptiveuse andreduced withoral anticoagulant therapy.
Introduction
ProteinZ( PZ)i sav itamin K-dependent plasma glycoprotein whose structureissimilartothat of factorsVII, IX, X, and protein C (1, 2) . In contrast to these serine protease zymogens, however,PZlacks the histidine and serine residuesofthe canonical catalytic site and does notserve aproteolytic function.Instead, PZ functionsasacofactor to enhance the inhibition of factor Xa by aserpintermedPZ-dependent protease inhibitor (ZPI) (3) (4) (5) . In addition to inhibiting factor Xa in aPZdependentfashion,ZPI also inhibits factor XIa in the absence of PZ (5) .
PlasmaPZlevelsin450 Red Cross blood donors spanneda broadrange(0.6-5.7 μg/mL) with amean concentration of 2.9 + 1.0 μg/mL in EDTAanticoagulated plasma ( ∼ 2.6 μg/mL, in citrated plasma) (6) .Oral anticoagulant treatment with vitamin K antagonists, sucha sw arfarin, reduces both the PZ antigen (1-16%) and its degree of γ -carboxylation (<1%) muchm ore than other vitamin K-dependent factors (6) . PZ and ZPI circulate as acomplexinplasma and in the normalcaseofexcess ZPI all the PZ in plasma is bound to ZPI (7) .
In mice, PZ deficiencyi sa ssociatedw ith ap rothrombotic phenotype and dramatically increases mortality in animals with the factor VLeiden mutation suggesting thatPZdeficiencymay be arisk factor forthrombotic disease in humans (8) .Studiesexploring the relationship betweenPZlevelsand ischemic stroke have produced conflicting results (9) (10) (11) (12) (13) (14) . Twor eported an association of strokewith lowPZlevels (9, 11) , anotherfound that aPZgenetic polymorphism(intron Fg79a),which is reportedly associatedwith reduced PZ plasma levels, protected fromstroke (12, 15) , and athird found an association of high PZ levels with stroke (10) . In twoadditional studies therew as no relationship between strokeand PZ levels (13, 14) . Recent studies have also reported arelationship between PZ deficiencyand the acute coronarysyndrome and earlyfetal wastage (16, 17) .
LowlevelsofPZare common in individualswith antiphospholipid antibodiesa nd area ssociatedw ith thrombotic complications in the antiphospholipid syndrome (18) (19) (20) . In regard to venous thrombosis,o ne study did not find ar elationship with lowl evelso fP Zi nasmall cohorto fp atients (9) and another study,inwhich PZ levels were notdetermined, failedtodetect a association with polymorphisms within the PZ gene (21) .
As yet, the relationship between ZPIl evelsa nd thrombotic disease has not beenexplored. The aim of the current study was to assess determinants of plasma levels of PZ and ZPI, as well as the potential association of plasma levels of these proteins with the risk of venous thrombosis in alarge population-basedcasecontrol study.
Studydesign

Study population
The Leiden ThrombophiliaStudy (LETS) includes 474consecu-tive,unselectedpatients aged 18-70years with afirst objectively diagnosedepisode of deepvenous thrombosis and 474age-and sex-matchedc ontrol subjects. Control subjects were friends/ partners of patients (22) . Since PZ is av itamin K-dependent plasma protein, individualsusing oral anticoagulation were excluded fromthis analysis (n=49). Citrate anticoagulated plasma samples, obtained >6 monthsa fter the thrombotic event,f rom 426patients and 471control subjects were testedfor PZ and ZPI. The 100% levels for PZ and ZPIwere definedastheir meanvalues in the control group of LETS (n=471).
Citrated plasma samples from an additional group of 20 individuals with venous thrombosis obtained during and four weeks after anticoagulant treatment were alsoevaluated (23) .
Immunoassays
The monoclonal/monoclonal sandwich immunoassayf or PZ (CV=6.5%) and polyclonal/monoclonalsandwich immunoassay for ZPI(CV=7.2%),were performed as previously described (7) . Samples were assayed at a100-fold dilution against astandard curve constructed with pooledn ormal plasma (George King Biomedical, Overland Park, KS).
INR
Prothrombint imesa nd INRs were determinedu sing Innovin (Dade Behring Inc.,Newark, DE) followingthe manufacturers instructions.
Statisticalanalysis
DeterminantsofPZand ZPI levels were assessed by t-tests and linear regression analysis. To calculatethe risk of venous thrombosis, PZ and ZPI levels were dichotomized at the 10 th and 90 th percentiles measuredi nt he control subjects. Odds ratios (OR) were calculatedasestimatesofthe relative risk,with 95% confidenceintervals (95%CI).
Resultsand discussion
DeterminantsofPZand ZPI levels As noted previously in anothergroupofnormal subjects (6),the range of PZ levels in the plasma samplesof471 control subjects wasbroad (15%-233%). Though less marked thanthe resultsfor PZ, ZPI also spannedawide range(33%-191%).
PZ and ZPIp lasma levels were similari nm en and women (mean difference PZ:4 %; 95%C I: -2%-11%;ZPI: -4%; 95% CI:-9%-1%, respectively)(Table1). Aplot of ZPI versusPZlevels in the control subjectssuggests that the levels of these proteins are related (linear regression analysis with ZPI as the dependent variable:s lope=0.32, 95% CI: 0.26-0.38; Y-intercept=67.5%,95%CI 61.0%-74.1%).W omen using oralcontraceptives had significantly(p<0.001) higher levels of both PZ and ZPIcompared with womenwho were notusing oral contraceptives(mean difference PZ:38.2%, 95% CI: 26.1%-50.2%; ZPI: 16.9%, 95% CI: 8.3%-25.5%) ( Table 1) . Oral anticoagulant treatment dramaticallyreduces the level of antigenic PZ in plasma (6) and the effect of this reduction in PZ levels on the plasma concentration of ZPI wasexamined by evaluating plasma samplesfrom 20 individualsduring and after treatment for venous thrombosis.Ineach case, the rise in plasma PZ (mean 8% vs.9 4%; 95% CI of the difference:6 8%-103%) that followedd iscontinuation of anticoagulant therapyw as associatedw ith an increase in the levelo fZ PI (mean 59%v s. 112%;95% CI of the difference:36%-70%) (Fig. 1) . As adirect effect of warfarin therapyonZPI plasma levels seemsunlikely, we concludethat the rise in ZPI levels followingdiscontinuation of warfarin is related to ayet to be establishedeffect of PZ on ZPI metabolism. Aportion of ZPI circulates as acomplexwith PZ and it is conceivablethat the rate of clearanceofthe PZ-ZPI complexdiffers from thatofZPI (or PZ)alone (7) . Alternatively, the synthesis, secretion or extra-plasma localization of one of the proteins maybeaffected by the presence of the other. 
PZ and ZPI levels and venous thrombosis
No relationshipb etween venous thrombosis and high (>90% percentile, not shown) or low(<10th percentile) levels of PZ or ZPI could be demonstrated in the overallc ase-controls tudy (Table 2) .Subgroup analysis suggested an association of lowlevels of PZ with venous thrombosis in men (OR: 2.4; 95% CI: 1.2-4.9) and in individuals older than 55 years (OR:3.3; 95% CI: 1.2-8.7) ( Table 2 ).
There wasnorelationship between the PZ or ZPI leveland thrombosis in those positive/negative for the factor VL eiden mutation and,incontrast to the reportofKemkes-Matthes et al (24) ,noeffect of the PZ (or ZPI) levelonage of onset of thrombosis in patients with the factor VLeiden mutation (n=82) was detected(data not shown).Itperhaps should be notedinthis regard thatany effect of PZ on thefactor VLeiden phenotype in humans is likelyt ob em uch more subtlet han that reported in mice (8) .I nc ontrast to the situation in humans, in the mice studied (C57Bl/6 x129 mixed genetic background) the homozygous factor VLeiden genotypeleads to asevere phenotype with 50% perinatal mortality (25) .Moreover,although the effect of PZ deficiencywas dramatic in murine factor VLeiden homozygotes, its effect in murine factor VL eiden heterozygotes was muchmore modest (8) .
Overall our results suggestthat severe deficienciesofPZand ZPI areunusual and that modestlyreduced levels of these proteins are notamajor risk factor forvenous thrombosis. Duetoincreased statisticalinstability,subgroup analysis suggesting that lowPZlevelsmay increase the risk of venous thrombosis in men and older individuals must be viewedwith caution. Nevertheless, it is of interest that this same patternofincreased thromboticrisk in menand older subjects wasnoted by Heeb and colleagues in their studies of theassociation of PZ with stroke(11).
Ongoing investigations should betterd efine the potential roles of both PZ and ZPIi na rterial as well as venous thromboembolic disease. The interdependence of the plasma levels of PZ and ZPIa nd the effect of oralc ontraceptive use and anticoagulant therapyontheir levels will need to be consideredwhen analyzing the results of these studies. dam 
